Save time and money with
Med Tech Market
Research
MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData
Forecast Insight: Antidiabetics — Switching to new molecule antidiabetics drives market growth
| Publication Date: August 2008 Publisher: Datamonitor Pages: 74
|
Price £7,600.00 approximately: $13,400 | €9,422
Buy
and download >>
|
Summary
Introduction
Datamonitor expects the antidiabetics market to reach $29 billion, across the seven major markets, by 2017.
The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.
Scope
- Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview.
- Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
- Analysis of major events and brand dynamics affecting the diabetes market.
Highlights
The antidiabetics market in the seven major markets is expected to grow from $18 billion in 2007 to $29 billion in 2017 at a rate of 5% CAGR. Significant unmet needs remain in diabetes fueling a large pipeline. The epidemiological growth of the market, driven by the obesity epidemic and improved diagnosis rates, is further driving the market.
The glitazone class was the major non-insulin antidiabetic therapy in 2007 driven by the Actos and Avandia franchises. Both of these drugs will lose their marketing leading positions following patent expiry in 2011 and 2013. Safety concerns over Avandia remain unresolved and the drug will continue to continue to lose market share.
The incretin mimetics are likely to be the beneficiaries of Avandia's problems and the DPP-IV inhibitors are expected to become the leading non-insulin antidiabetics. GLP-1 agonists are also expected to record significant sales. The two classes will provide over 75% of the sales from newly launched antidiabetics.
Reasons to Purchase
- Quantify the future size of the antidiabetics market and identify opportunities for new products.
- Learn how product expiries will shape the antidiabetics market.
- Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews.
Contents
- About Datamonitor Healthcare
- About The Cardiovascular And Metabolic Pharmaceutical Analysis Team
- Chapter 1 Executive Summary
- Strategic Scoping And Focus
- Datamonitor Insight Into The Disease Market
- Related Reports
- Chapter 2 Market Definition And Overview
- Definition Of Drug Classes
- Current Seven Major Market Assessment
- The Antidiabetics Market Segmented By Class
- Total Antidiabetic Market
- Insulin Therapies
- Non-Insulin Therapies
- The Us Dominates Diabetes Market
- Historical Events
- Rest Of World Snapshot
- Current Market Assessment
- Future Seven Major Market Assessment
- Chapter 3 Brand Dynamics
- Overview Of Competitive Landscape
- Actos Franchise (Pioglitazone; Takeda)
- Franchise Overview
- Sales Forecasts
- Avandia Franchise (Rosiglitazone; Glaxosmithkline)
- Franchise Overview
- Sales Forecasts
- Byetta (Exenatide; Amylin/Eli Lilly)
- Overview
- Sales Forecast
- Humalog (Insulin Lispro; Eli Lilly)
- Overview
- Sales Forecast
- Humalog Mix (Insulin Lispro + Insulin Lispro Protamine; Eli Lilly)
- Overview
- Sales Forecast
- Januvia Franchise (Sitagliptin; Merck & Co)
- Franchise Overview
- Sales Forecast
- Lantus (Insulin Glargine; Sanofi-Aventis)
- Overview
- Sales Forecast
- Novomix (Insulin Aspart; Novo Nordisk)
- Overview
- Sales Forecast
- Novorapid (Insulin Aspart + Insulin Aspart Protamine; Novo Nordisk)
- Overview
- Sales Forecast
- Bibliography
- Journal Papers
- Websites
- Appendix - Market Assumption
- New Product Launches
- Patent Expiries
- Data Definitions, Limitations And Assumptions
- Standard Units
- Japanese Market Data
- Derivation Of Sales Forecasts And Pricing Trends
- Forecast Methodology
- About Datamonitor Healthcare
- Datamonitor Healthcare's Therapy Area Capabilities
- About The Disease Analysis Team
- Disclaimer
- List Of Tables
- Table 1: Antidiabetic Sales In The Seven Major Markets By Class, 2006-07
- Table 2: Comparison Of Leading Branded Drug Sales ($M) For Osteoarthritis In The 7mm And The Rest Of World (Row), 2007
- Table 3: Sales Forecasts In Diabetes In The 7mm ($M), 2007-2017
- Table 4: Leading Branded Drug Sales ($M) For Diabetes, 2007-2017
- Table 6: Actoplus Met: Key Facts
- Table 7: Duetact: Key Facts
- Table 8: Sales Forecast ($M) For The Actos Franchise For Diabetes In The Seven Major Markets, 2007-2017
- Table 9: Impacting Factors On The Revenues Of The Actos Franchise, 2007-17
- Table 10: Avandia: Key Facts
- Table 11: Avandamet: Key Facts
- Table 12: Avandaryl: Key Facts
- Table 13: Sales Forecast ($M) For The Avandia Franchise For Diabetes In The Seven Major Markets, 2007-2017
- Table 14: Impacting Factors On The Revenues Of The Avandia Franchise, 2007-17
- Table 15: Byetta: Key Facts
- Table 16: Sales Forecast ($M) For Byetta For Diabetes In The Seven Major Markets, 2007-2017
- Table 17: Impacting Factors On The Revenues Of Byetta, 2007-17
- Table 18: Humalog: Key Facts
- Table 19: Sales Forecast ($M) For Humalog For Diabetes In The Seven Major Markets, 2007-2017
- Table 20: Impacting Factors On The Revenues Of Humalog, 2007-17
- Table 21: Humalog Mix: Key Facts
- Table 22: Sales Forecast ($M) For Humalog Mix For Diabetes In The Seven Major Markets, 2007-2017
- Table 23: Impacting Factors On The Revenues Of Humalog, 2007-17
- Table 24: Januvia: Key Facts
- Table 25: Janumet: Key Facts
- Table 26: Sales Forecast ($M) For The Januvia Franchise For Diabetes In The Seven Major Markets, 2007-2017
- Table 27: Impacting Factors On The Revenues Of The Januvia Franchise, 2007-17
- Table 28: Lantus: Key Facts
- Table 29: Sales Forecast ($M) For Lantus For Diabetes In The Seven Major Markets, 2007-2017
- Table 30: Impacting Factors On The Revenues Of Lantus, 2007-17
- Table 31: Novomix: Key Facts
- Table 32: Sales Forecast ($M) For Novomix For Diabetes In The Seven Major Markets, 2007-2017
- Table 33: Impacting Factors On The Revenues Of Novomix, 2007-17
- Table 34: Novorapid: Key Facts
- Table 35: Sales Forecast ($M) For Novorapid For Diabetes In The Seven Major Markets, 2007-2017
- Table 36: Impacting Factors On The Revenues Of Novorapid, 2007-17
- Table 37: Datamonitor's Launch Dates For Diabetes Products In The 7mm, 2007-2017
- List Of Figures
- Figure 1: Diabetes Sales In The Us, 5eu And Japan, ($ Billion), 2004-07
- Figure 2: Diabetes Market Sales By Class In The 7mm, 2004-07
- Figure 3: Sales Performance Of The Us, 5eu And Japanese Diabetes Markets, 2006-07
- Figure 4: Key Events Impacting The Diabetes Market 2005-2008
- Figure 5: Annual Global Sales In The Diabetes Market, ($M), 2004-07
- Figure 6: Row Vs. 7mm Sales ($M) Split In The Diabetes Market, 2007
- Figure 7: Diabetes Sales By Class In The 7mm, 2007-2017
- Figure 8: Market Share Of Drug Classes For Diabetes, 2007 Vs. 2017
- Figure 9: Antidiabetic Sales ($M) Forecast For The Actos Franchise In The Seven Major Markets, 2007-2017
- Figure 10: Glitazone Market Split In The 7mm - Actos Vs Avandia (2004-2010)
- Figure 12: Antidiabetic Sales ($M) Forecast For Byetta In The Seven Major Markets, 2007-2017
- Figure 13: Antidiabetic Sales ($M) Forecast For Humalog In The Seven Major Markets, 2007-2017
- Figure 14: Antidiabetic Sales ($M) Forecast For Humalog Mix In The Seven Major Markets, 2007-2017
- Figure 15: Antidiabetic Sales ($M) Forecast For The Januvia Franchise In The Seven Major Markets, 2007-2017
- Figure 16: Antidiabetic Sales ($M) Forecast For Lantus In The Seven Major Markets, 2007-2017
- Figure 17: Antidiabetic Sales ($M) Forecast For Novomix In The Seven Major Markets, 2007-2017
- Figure 18: Antidiabetic Sales ($M) Forecast For Novorapid In The Seven Major Markets, 2007-2017
- Figure 19: Patent Expiry Dates Used In Forecasting Antidiabetic Drugs In The 7mm, 2007-2016
Buy now >>